Burden of disease: Medical and economic impact of acute coronary syndromes

American Journal of Managed Care

Volumn 12, Issue SUPPL. 16, 2006, Pages

  Turpie, Alexander G G ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ARTICLE; CAUSE OF DEATH; DATA BASE; DRUG COST; HEALTH CARE COST; HEART DEATH; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; ST SEGMENT ELEVATION; UNITED STATES; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; CARDIOVASCULAR DISEASES; COST OF ILLNESS; HUMANS; UNITED STATES;

EID: 33846020067     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bosanquet N, Jonsson B, Fox KAA. Costs and cost effectiveness of low molecular weight heparins and platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes. Pharmacoeconomics. 2003;21:1135-1152.
2. Moliterno DJ, Granger CB. Chapter 6. Differences between unstable angina and acute myocardial infarction. In: Topol E, ed. Acute Coronary Syndromes. New York, NY: Marcel Dekker; 1998:135-172.
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893-1900.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:e82-e292.
5. Palmer S, Sculpher M, Philips Z, et al. Management of non-ST-elevation acute coronary syndromes: How cost-effective are glycoprotein IIb/IIIa antagonists in the UK National Health Service? Int J Cardiol. 2005;100:229-240.
6. Collinson J, Flather MD, Fox KAA, et al; for the PRAIS-UK Investigators. Clinical outcomes, risk stratification, and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). Eur Heart J. 2000;21:1450-1457.
7. Thom T, Haase N, Rosemond W, et al. Heart Disease and Stroke Statistics-2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113: e85-e151.
8. John Ayanian JZ, Hauptman PJ, Guadagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136-1142.
9. Tu K, Gong Y, Austin PC, Jaakimanian L, Tu JV; Canadian Cardiovascular Outcomes Research Team. An overview of the types of physicians treating acute cardiac conditions in Canada. Can J Cardiol. 2004;20:282-291.
10. Schreiber TL, Elkhatib A, Grines CL, O'Neill WW. Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes. J Am Coll Cardiol. 1995;26:577-582.
11. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
12. Section 16: coronary artery disease. Chapter 202: angina pectoris. In: The Merck Manual. Available at: http://www.merck.com. Accessed October 3, 2006.
13. Fox KAA, Goodman SG, Klein W, et al. Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177-1189.
14. Theroux P, Lidon RM. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol. 1993;18:157-231.
15. CRUSADE Slide Sets: Quarter 2, 2006 Results. Available at: www.crusadeqi.com/. Accessed October 17, 2006.
16. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
17. Califf RM. Matching resources to treatment decisions for patients with acute coronary syndromes. In: Califf RM, ed. Redefining Acute Coronary Syndrome Care in the Era of Aggressive Revascularization. Clin Cardiol. 2002;25(11 suppl 1):I2-I8.
18. Kauf TL, Velazquez EJ, Crosslin DR, et al. The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. Am Heart J. 2006;151:206-212.
19. Fox AC, Levin RI. Ruptured plaques and leaking cells: cost effectiveness in the diagnosis of acute coronary syndromes. Ann Intern Med. 1999;131: 968-970.
20. Cannon CP, Hand MH, Bahr R, et al. Critical pathways for management of patients with acute coronary syndromes: an assessment by the National Heart Attack Alert Program. Am Heart J. 2002;143:777-789.
21. Conti A, Pieralli F, Sammicheli L, et al. Updated management of non-ST-segment elevation acute coronary syndromes: selection of patients for low-cost care: an analysis of outcome and cost-effectiveness. Med Sci Monit. 2005;11:CR100-CR108.
22. Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS. Cost-effectiveness of diagnostic strategies for patients with chest pain. Ann Intern Med. 1999;130:709-718.
23. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216-235.
24. Hirsch J. Antithrombotic therapy. In: Goldman L, Ausiello D, eds. Cecil Textbook of Medicine. 22nd ed. Philadelphia, Pa: Saunders; 2004:161-170.
25. Morris TA. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med. 2003;24:39-47.
26. Nutescu E, Racine E. Traditional versus modern anticoagulant strategies: summary of the literature. Am J Health Syst Pharm. 2002;59(20 suppl 6):S7-S14.
27. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
28. Büller HR, Davidson BL, Decousus H, et al; for the MATISSE Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med. 2004;140:867-873.
29. Bergqvist D. Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics. 2002;20:225-243.
30. The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-1476.
31. The OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295: 1519-1530.